Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal
- Conditions
- Schizophrenia
- Registration Number
- NCT00314613
- Lead Sponsor
- Duke University
- Brief Summary
Assured treatment with Risperal CONSTA will provide first-episode patients, who have a greater potential for therapeutic response, with their best opportunity for continued improvement in cognitive function beyond three months of treatment.
- Detailed Description
First episode patients have a greater potential for therapeutic response than multi-episode patients, and many of them also havea great desire to rejoin the workforce. Unfortunately, first episode patients become non-compliant or intermittently compliant with prescribed antipsychotic treatment at least as frequently as multi-episode patients. We believe that assured treatment with Risperal CONTSTA will provide first episode patients wiwth their best opporutnity for continued improvement in cognitive function beyond 3 months of treatment and that improvements in cognitive function will be associated with a greater likelihood of employment, real-world outcomes, such as independent living, as well as measures of brain function.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 30
- male or female between 18-40 years of age
- meet DSM-IV criteria for first-episode schizophreniform, schizophrenia or schizoaffective disorder
- pregnant & breast-feeding women
- patients with known sensitivity to oral Risperdal
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
John Umstead Hospital
🇺🇸Butner, North Carolina, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States